Vitreous concentration of topically applied brimonidine tartrate 0.2%

Ophthalmology

Volumn 108, Issue 4, 2001, Pages 784-787

  Kent, Alexander R ^a   Nussdorf, Jonathan D ^b   David, Robert ^c   Tyson, Farrell ^a   Small, David ^c   Fellows, Dan ^d  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b Oschner Clinic   (United States)

^c ALLERGAN INC   (United States)

^d Oneida Research Services Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRIMONIDINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; MALE; NERVE DEGENERATION; NEUROTRANSMITTER RELEASE; PRIORITY JOURNAL; PSEUDOPHAKIA; RETINA GANGLION CELL; VITRECTOMY; VITREOUS BODY;

EID: 0035082121     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(00)00654-0     Document Type: Article

References (11)

1. Vascular dysregulation: A principal risk factor for glaucomatous damage?
2. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma
3. Quantitative study of collagen and elastin of the optic nerve head and sclera in human and experimental monkey glaucoma
4. Alpha2-adkenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration
5. 2 agonist pathway is neuroprotective in models of retinal and optic nerve injury
6. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension
7. Preclinical evaluation of brimonidine
8. Brimonidine: A new alpha2-adrenoreceptor agonist for glaucoma treatment
9. Effects of brimonidine 0.2% on blue-yellow perimetry of glaucomatous patients
10. Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits
11. Alpha 2-adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors in vivo and ameliorate light damage